LENZ Therapeutics Inc (LENZ) - Net Assets
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has net assets worth $284.34 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($305.88 Million) and total liabilities ($21.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of LENZ Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $284.34 Million |
| % of Total Assets | 92.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LENZ Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how LENZ Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore LENZ total asset value for the complete picture of this company's asset base.
Annual Net Assets for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual net assets of LENZ Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see how much is LENZ Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $284.34 Million | +39.32% |
| 2024-12-31 | $204.08 Million | +320.13% |
| 2023-12-31 | $-92.71 Million | -283.60% |
| 2022-12-31 | $-24.17 Million | -70.04% |
| 2021-12-31 | $-14.21 Million | -45.04% |
| 2020-12-31 | $-9.80 Million | -341.84% |
| 2019-12-31 | $-2.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LENZ Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22492300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $242.00K | 0.09% |
| Other Components | $511.24 Million | 179.80% |
| Total Equity | $284.34 Million | 100.00% |
LENZ Therapeutics Inc Competitors by Market Cap
The table below lists competitors of LENZ Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
$278.49 Million |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
$278.53 Million |
|
STIF Société anonyme
PA:ALSTI
|
$278.58 Million |
|
H+H International A/S
CO:HH
|
$278.62 Million |
|
MEDI ASSIST HEALTHCARE SERVICES LIMITED
NSE:MEDIASSIST
|
$278.41 Million |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
$278.32 Million |
|
Wiz Soluções e Corretagem de Seguros S.A
SA:WIZC3
|
$278.31 Million |
|
Beyond Meat Inc
NASDAQ:BYND
|
$278.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LENZ Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 204,084,000 to 284,339,000, a change of 80,255,000 (39.3%).
- Net loss of 82,127,000 reduced equity.
- New share issuances of 147,749,000 increased equity.
- Other comprehensive income increased equity by 46,000.
- Other factors increased equity by 14,587,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-82.13 Million | -28.88% |
| Share Issuances | $147.75 Million | +51.96% |
| Other Comprehensive Income | $46.00K | +0.02% |
| Other Changes | $14.59 Million | +5.13% |
| Total Change | $- | 39.32% |
Book Value vs Market Value Analysis
This analysis compares LENZ Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.27 | $8.88 | x |
| 2020-12-31 | $-1.18 | $8.88 | x |
| 2021-12-31 | $-1.72 | $8.88 | x |
| 2022-12-31 | $-3.08 | $8.88 | x |
| 2023-12-31 | $-11.38 | $8.88 | x |
| 2024-12-31 | $9.59 | $8.88 | x |
| 2025-12-31 | $9.87 | $8.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LENZ Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -430.25%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.08x
- Recent ROE (-28.88%) is below the historical average (-7.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $112.80K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-67.39 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-69.34 Million |
| 2022 | 0.00% | -72.07% | 0.32x | 0.00x | $-8.39 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-60.70 Million |
| 2024 | -24.39% | 0.00% | 0.00x | 1.05x | $-70.18 Million |
| 2025 | -28.88% | -430.25% | 0.06x | 1.08x | $-110.56 Million |
Industry Comparison
This section compares LENZ Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LENZ Therapeutics Inc (LENZ) | $284.34 Million | 0.00% | 0.08x | $278.43 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more